These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17684975)

  • 1. [Current modalities in immunotherapy of renal cell carcinoma].
    Aliaev IuG; Grigorian VA; Shpot' EV
    Ter Arkh; 2007; 79(6):78-82. PubMed ID: 17684975
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene-modified immunotherapy for renal cell carcinoma.
    Kawai K; Tani K; Asano S; Akaza H
    Contrib Nephrol; 1999; 128():75-81. PubMed ID: 10597379
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarker classification, validation, and what to look for in 2017 and beyond.
    Davis JW
    BJU Int; 2017 May; 119(5):812-814. PubMed ID: 28117555
    [No Abstract]   [Full Text] [Related]  

  • 4. Metastasectomy plus immunotherapy compared with immunotherapy alone in metastatic renal cell carcinoma.
    Ku JH; Kwak C
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):164-5. PubMed ID: 17355116
    [No Abstract]   [Full Text] [Related]  

  • 5. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
    Schmitz-Dräger BJ
    Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
    Négrier S
    J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
    [No Abstract]   [Full Text] [Related]  

  • 8. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell cancer--a multimodal approach to preserving renal function and improving survival.
    Hohenfellner M; Pahernik S; Jaeger D; Zeier M
    Nephrol Dial Transplant; 2011 Oct; 26(10):3086-8. PubMed ID: 21622992
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view.
    Mickisch GH
    Urol Int; 1999; 63(1):16-21. PubMed ID: 10592485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma.
    Sawczuk IS
    Urol Clin North Am; 1993 May; 20(2):297-301. PubMed ID: 8493751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs?].
    Oberneder R; Kriegmair M; Staehler M; Hofstetter A
    Urologe A; 1997 Mar; 36(2):130-7. PubMed ID: 9199040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
    Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
    J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
    Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
    J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urologic approaches to metastatic renal cell carcinoma.
    Mickisch GH
    Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.